Senators Join Biosimilar Coding Debate, Ask CMS To Withhold Draft Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
A bipartisan group of 20 US senators wrote to the Centers for Medicare and Medicaid Services asking that it not issue rules on how Medicare will reimburse biosimilars until the Food and Drug Administration has completed its regulations for the products.
You may also be interested in...
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
Are Manufacturers Willing To Do Outcomes-Based Pricing? Payers Are Skeptical
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.